Supplemental material
Open access
3,273
Views
18
CrossRef citations to date
0
Altmetric
Transformation of Mental Health & Brain Disorders Management
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Patricia Pozo-Rosicha Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain;b Headache and Neurological Pain Research Group, Vall d’Hebron Institute of Research (VHIR), Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
, Holland C. Detkec Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
https://orcid.org/0000-0002-1316-6064
Shufang Wangc Eli Lilly and Company, Indianapolis, IN, USA;f Now at Sarepta Therapeutics, Cambridge, MA, USA
, David Doležild Prague Headache Center, DADO MEDICAL s.r.o, Prague, Czech Republic
, Lily Q. Lic Eli Lilly and Company, Indianapolis, IN, USA
, Sheena K. Aurorac Eli Lilly and Company, Indianapolis, IN, USA;g Now at Impel NeuroPharma, Seattle, WA, USA
& Uwe Reutere Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany
show all
Pages 731-742
|
Received 07 Jan 2022, Accepted 28 Mar 2022, Published online: 15 Apr 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.